Joyeeta Roy

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Squamous Cell Carcinoma

Simultaneous Determination

Clinical Evaluation

Top Venues

Journal of medicinal chemistry

Pharmaceuticals (Basel, Switzerland)

ACS pharmacology & translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, Ranjan Kumar Acharyya, I N Chaithanya Kiran, Yesu Addepalli, V Dhamodharan
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, Ranjan Kumar Acharyya, I N Chaithanya Kiran, Yesu Addepalli, V Dhamodharan
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Joyeeta Roy, Armita Kyani, Maha Hanafi, Yibin Xu, John Takyi-Williams, Duxin Sun, Essam Eldin A Osman, Nouri Neamati
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Journal of medicinal chemistry (2023)
Joyeeta Roy, Armita Kyani, Maha Hanafi, Yibin Xu, John Takyi-Williams, Duxin Sun, Essam Eldin A Osman, Nouri Neamati
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Journal of medicinal chemistry 66 (3) (2023)
Yibin Xu, Ding Xue, Armita Kyani, Armand Bankhead, Joyeeta Roy, Mats Ljungman, Nouri Neamati
First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer. ACS pharmacology & translational science 6 (8) (2023)
Joyeeta Roy, Armita Kyani, Maha Hanafi, Yibin Xu, John Takyi-Williams, Duxin Sun, Essam Eldin A Osman, Nouri Neamati
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Journal of medicinal chemistry 66 (3) (2023)
Joyeeta Roy, Armita Kyani, Maha Hanafi, Yibin Xu, John Takyi-Williams, Duxin Sun, Essam Eldin A Osman, Nouri Neamati
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. Journal of medicinal chemistry 66 (3) (2023)